在本次大会上,一项题为“Validation of the 2022 European Leukemianet Risk Stratification of Acute Myeloid Leukemia(2022年欧洲白血病网(ELN)急性髓系白血病(AML)风险分层的验证)”的研究入选壁报展示(P4310),为AML风险分层带来重要启示。...
在2017年,ELN进行了首次更新[1],ELN对于AML的危险度分层已经广泛应用于临床实践中,用于AML的诊断和风险评估。最近更新的ELN 2022建议修订了遗传风险分类[2],该分类纳入了AML遗传改变与预后意义方面的最新进展,其中主要的分子遗传学更新内容包括:...
在本次大会上,一项题为“Validation of the 2022 European Leukemianet Risk Stratification of Acute Myeloid Leukemia(2022年欧洲白血病网(ELN)急性髓系白血病(AML)风险分层的验证)”的研究入选壁报展示(P4310),为AML风险分层带来重要启示。本期特整理如下,供大家提前阅览。 研究简介 背景 AML在临床结局和疾病生物学...
在本次大会上,一项题为“Validation of the 2022 European Leukemianet Risk Stratification of Acute Myeloid Leukemia(2022年欧洲白血病网(ELN)急性髓系白血病(AML)风险分层的验证)”的研究入选壁报展示(P4310),为AML风险分层带来重要启示。本期特整理如下,供大家提前阅览。 研究简介 背景 AML在临床结局和疾病生物学...
Due to the small number of prospective Minimal Residual Disease (MRD) driven studies, the MRD role in AML risk stratification is not clearly defined.The aim of this study was to evaluate the effect of MRD in a real-life setting. We retrospectively analyzed 124 patients with Favorable (FAV) ...
2022_ELN_Favorable_Code.Rmd R code for replicating results in Archer et al., "Improving risk stratification for 2022 European LeukemiaNet favorable-risk patients with acute myeloid leukemia" hdcuremodels The hdcuremodels R package was used for fitting high-dimensional mixture cure models. A vignett...
We conducted a retrospective, single-center study to investigate the impact of hyperleukocytosis on the response and prognosis of favorable-risk AML according to ELN-2022 risk classification. Method: We retrospectively enrolled 217 favorable-risk AML patients, excluding acute promyelocytic leukemia (APL)...
et al. Lomustine is beneficial to older AML with ELN2017 adverse risk profile and intermediate karyotype: a FILO study. Leukemia 35, 1291–1300 (2021). https://doi.org/10.1038/s41375-020-01031-1 Download citation Received27 April 2020 Revised23 July 2020 Accepted14 August 2020 Published18 ...
ELN2017 risk group ELN2017-IR vs ELN2017-FR .0003 1.838 1.321 2.557 Transplant, covariate time-dependent Transplant vs no transplant .0185 0.674 0.485 0.936 Discussion In the current analysis, we showed that, when implemented in the prospective, risk-adapted, MRD-driven, AML1310 GIMEMA protocol...
For most patients with acute myeloid leukemia (AML), an allogeneic hematopoietic stem cell transplantation (HSCT) offers the highest chance of cure. Recently, the European LeukemiaNet (ELN) published updated recommendations on the diagnosis and risk classification in AML based on genetic factors at ...